간행물

대한당뇨병학회> 당뇨병(JKD)

당뇨병(JKD) update

The Journal of Korean Diabetes

  • : 대한당뇨병학회
  • : 의약학분야  >  내과학
  • :
  • :
  • : 연속간행물
  • : 계간
  • : 2233-7431
  • : 2714-0547
  • : 임상 당뇨병(~2010)→ 당뇨병(JKD)(2011~)

수록정보
수록범위 : 1권1호(2000)~22권2호(2021) |수록논문 수 : 982
당뇨병(JKD)
22권2호(2021년 06월) 수록논문
최근 권호 논문
| | | |

1Opinion : 코로나 시대, 당뇨병 환자의 홈트레이닝

저자 : 김현준 ( Hyunjun Kim )

발행기관 : 대한당뇨병학회 간행물 : 당뇨병(JKD) 22권 2호 발행 연도 : 2021 페이지 : pp. 71-76 (6 pages)

다운로드

(기관인증 필요)

초록보기

Due to the coronavirus disease 2019 (COVID-19) pandemic, people's physical activity has declined by 35% because their time spent at home has increased. Decreased physical activity can increase both the number of people with type 2 diabetes annually by more than 11.1 million and the number of deaths by more than 1.7 million. Thus, exercise is important during the COVID-19 pandemic, especially in relation to diabetes. If a person with the COVID-19 virus lacks exercise, the risk of hospitalization is increased by 2.2 times and the risk of death by 2.5 times. In the context of COVID-19, the purpose of home training for patients with diabetes mellitus is to reduce body fat percentage, increase muscle function and mass, and improve insulin resistance. The recommended home training program is a circuit-based exercise regime that combines aerobic exercise and strength exercise. In addition, muscle stretching exercises are recommended for home training programs to increase muscle function.

2Statement : 청소년 당뇨병, 성인기로의 적절한 이행

저자 : 이지은 ( Jieun Lee ) , 김재현 ( Jae Hyun Kim )

발행기관 : 대한당뇨병학회 간행물 : 당뇨병(JKD) 22권 2호 발행 연도 : 2021 페이지 : pp. 77-84 (8 pages)

다운로드

(기관인증 필요)

초록보기

As the prevalence of diabetes in children and adolescents increases, the transition of diabetes care from childhood to adulthood is increasing. During the transition period, the risks for hypoglycemia and hyperglycemia as well as microvascular and macrovascular complications can increase due to poor glycemic control along with mental health problems and high-risk behaviors. It is necessary to prepare and plan for the transition to the adult care system so that diabetes care is properly implemented, reducing the risk of complications and fostering successful diabetes management. The transition should begin at least 1 year prior to transfer and should focus on patient diabetes self-management skills. Pediatric providers should prepare a summary of the patient's medical records, including current mental health problems and presence of complications. Adult providers should be aware of and take into account the characteristics of emerging adults in management of diabetes, which are different from those of older adults. For successful transition, it is necessary to spend more time, consider mental health problems and high-risk behaviors, and communicate and exchange information with the pediatric provider. To this end, it is necessary for academia to develop a systematic, specific, and practical transition program and protocols and to develop a transition training program for pediatric and adult providers.

3Focused Issue : 메트포민의 최신지견

저자 : 홍상모 ( Sangmo Hong )

발행기관 : 대한당뇨병학회 간행물 : 당뇨병(JKD) 22권 2호 발행 연도 : 2021 페이지 : pp. 85-90 (6 pages)

다운로드

(기관인증 필요)

초록보기

Metformin has been used clinically more than 60 years in type 2 diabetes as the first-line drug for treatment. Metformin has been prescribed in more than 80% of Korean patients with diabetes. Despite long-term use and wide prescription of metformin in patients with type 2 diabetes, many questions remain. Recent advances have revealed a new mechanism of action and new benefits of metformin. In this article, we review recent advances regarding metformin treatment.

4Focused Issue : Dipeptidyl Peptidase 4 억제제 최신지견

저자 : 이주희 ( Ju Hee Lee )

발행기관 : 대한당뇨병학회 간행물 : 당뇨병(JKD) 22권 2호 발행 연도 : 2021 페이지 : pp. 91-96 (6 pages)

다운로드

(기관인증 필요)

초록보기

Dipeptidyl peptidase 4 (DPP4) inhibitors, one of the most prescribed second-line antidiabetic drugs in South Korea, have been available since 2006. Many studies focusing on the safety profiles of DPP4 inhibitors have been reported. DPP4 inhibitors were associated with a small increased incidence of acute pancreatitis in placebo-controlled trials, although most observational studies did not support this hypothesis. There were no significant differences in major cardiovascular events in a large prospective cardiovascular outcomes trial with DPP4 inhibitors, although a higher risk of hospitalization for heart failure was reported with saxagliptin. Additionally, the safety data of DPP4 inhibitors for diabetes management during the coronavirus disease-19 (COVID-19) pandemic have been provided recently.

5Focused Issue : Thiazolidinedione 최신지견

저자 : 김원준 ( Won Jun Kim )

발행기관 : 대한당뇨병학회 간행물 : 당뇨병(JKD) 22권 2호 발행 연도 : 2021 페이지 : pp. 97-104 (8 pages)

다운로드

(기관인증 필요)

초록보기

Thiazolidinedione (TZD) is an insulin sensitizer that improves insulin resistance in the adipose tissue, liver, and muscles and has a pancreas-protective effect while inhibiting gluconeogenesis. Its other advantages include a glucose lowering effect, its durability, cardiovascular benefit, and recent evidence in nonalcoholic fatty liver disease and dementia. However, there are also concerns about fluid retention/ edema/heart failure, bladder cancer, and fractures with TZD use. TZD can still be a useful option for diabetes treatment when calculating risk versus benefit, but appropriate selection of patients is needed.

6Focused Issue : 설포닐유레아 최신지견

저자 : 김태년 ( Tae Nyun Kim )

발행기관 : 대한당뇨병학회 간행물 : 당뇨병(JKD) 22권 2호 발행 연도 : 2021 페이지 : pp. 105-112 (8 pages)

다운로드

(기관인증 필요)

초록보기

Sulfonylureas (SUs) are widely prescribed in the treatment of type 2 diabetes. Despite the availability of several newer agents, SUs still play an important role in glucose-lowering therapy. However, over the last decade, there is a degrowth of older agents (SUs and thiazolidinediones) prescriptions with emergence of newer agents such as dipeptidyl peptidase-4 inhibitors, sodium glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists. The role of SUs in modern clinical practice poses ongoing clinical debate. With active marketing of these newer drugs, the concerns regarding hypoglycemia, secondary failure and cardiovascular safety tend to be overstated, especially when considering SUs. Some evidence has suggested that modern SUs (such as gliclazide modified release and glimepiride) have lower hypoglycemia and secondary failure rates and decreased risk of mortality from all-cause and cardiovascular disease compared to conventional SUs in patients with type 2 diabetes. Appropriate clinical judgement coupled with a patient-centered approach is crucial to achieve the best outcome in patients with type 2 diabetes. Modern SUs should also be considered based on their safety, efficacy, and low cost when choosing anti-hyperglycemic agents.

7Focused Issue : Sodium Glucose Cotransporter-2 억제제의 최신지견

저자 : 조동혁 ( Dong Hyeok Cho )

발행기관 : 대한당뇨병학회 간행물 : 당뇨병(JKD) 22권 2호 발행 연도 : 2021 페이지 : pp. 113-125 (13 pages)

다운로드

(기관인증 필요)

초록보기

Sodium glucose cotransporter-2 inhibitors (SGLT2i) block SGLT2 in the renal proximal tubule and increase the excretion of glucose into the urine, thereby decreasing serum glucose concentrations. These glucose-lowering effects are independent of insulin action. SGLT2i has been demonstrated to reduce cardiovascular complications and hospitalization for heart failure. SGLT2i has also shown remarkable inhibition effects on the progression of renal complications, decreasing serum creatinine, reducing albuminuria, and decreasing death from renal disease. These cardiorenal protective effects appear to be independent of glycemic control efficacy, and in view of these results, SGLT2i is recommended in type 2 diabetes patients at high risk of cardiovascular or renal disease. This review aims to provide an update on the mechanisms, efficacy, cardiorenal protective effects, and adverse effects of SGLT2i.

8Focused Issue : Glucagon-Like Peptide 1 수용체작용제 최신지견

저자 : 김혜진 ( Hae Jin Kim )

발행기관 : 대한당뇨병학회 간행물 : 당뇨병(JKD) 22권 2호 발행 연도 : 2021 페이지 : pp. 126-133 (8 pages)

다운로드

(기관인증 필요)

초록보기

Glucagon-like peptide 1 (GLP-1) is a peptide hormone secreted by L cells of the small intestine in response to nutrients. GLP-1 presents a glucose-lowering effect via insulinotropic action on pancreatic β-cells. In addition to the insulinotropic effect, GLP-1 has pleiotropic actions associated with clinical benefits. GLP-1 receptor agonists (GLP-1RAs) are a well-established effective treatment for patients with type 2 diabetes mellitus (T2DM). GLP-1RAs have antihyperglycemic effects and help reduce glucose levels and body weight, with a low risk of hypoglycemia. Additionally, GLP-1RAs have beneficial effects on cardiovascular risk factors, such as blood pressure and lipid levels. Large randomized cardiovascular outcome trials and meta-analyses have demonstrated that GLP-1RAs reduce cardiovascular disease in T2DM patients. GLP-1RAs are recommended as part of glucose-lowering regimens in patients with T2DM and established cardiovascular disease or those at high risk. Renal protective effects and beneficial effects of GLP-1RAs on non-alcoholic fatty liver disease have been suggested.

9Information Desk : 당뇨병 관리의 새로운 패러다임 접근: 병원과 지역사회의 자원 연계 및 활용 전략

저자 : 이향열 ( Hyang Yuol Lee )

발행기관 : 대한당뇨병학회 간행물 : 당뇨병(JKD) 22권 2호 발행 연도 : 2021 페이지 : pp. 134-141 (8 pages)

다운로드

(기관인증 필요)

초록보기

Diabetes Mellitus is a chronic disease that can be fatal to high-risk patients infected with the coronavirus. Many diabetic patients have been treated in a hospital setting. The coronavirus era is driving new approaches to how to manage diabetes. We belong to the community and a more therapeutic and supportive environment will make us healthier. Many resources are available in communities, but they are not utilized to their full extent because patients are treated in a traditional way, mostly at a hospital or clinic. Therefore, patient care is often redundant and segmented, and sometimes patients do not receive the simple and cost-effective care they need. Care coordination and an integrated approach could be one solution to these problems. Patients and doctors should be aware of the availability of hospital-based home healthcare and integrated healthcare services from community health centers that provide high-quality at-home care. A continuous health education program using health information technology could be a good way to increase diabetic patients' compliance with self-care, especially medication compliance, therapeutic meals, and daily exercise.

10Information Desk : 가정간편식, 배달형 식사와 관련된 당뇨병 환자의 혈당 관리

저자 : 노민영 ( Min Young Noh )

발행기관 : 대한당뇨병학회 간행물 : 당뇨병(JKD) 22권 2호 발행 연도 : 2021 페이지 : pp. 142-146 (5 pages)

다운로드

(기관인증 필요)

초록보기

Dietary management is an important factor in glycemic control among patients with diabetes mellitus. However, the range of food choices in diabetic diets is limited, increasing the amount of effort and time required to prepare meals. Home meal replacement and delivery meal services are a convenient and easy way to obtain meals prepared outside the home. The market is growing rapidly due to the increase in single-person households and the lifestyle change that prioritizes convenience. Therefore, in this paper, we review the recent revised notices from the Ministry of Food and Drug Safety related to home meal replacement and delivery meal services, and consider how home meal replacement and delivery meal services will affect blood sugar management in patients with diabetes mellitus.

12
권호별 보기

내가 찾은 최근 검색어

최근 열람 자료

맞춤 논문

보관함

내 보관함
공유한 보관함

1:1문의

닫기